A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > COMMENTARY
COMMENTARY
- 5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
- COMMENTARY：New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
- COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
- COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
- Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
- Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
- COMMENTARY 3 articles
June 19, 2006
- Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
- Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
- Incident in PI Trial in UK 5 articles
May 8, 2006
- COMMENTARY 3 articles
April 24, 2006
- New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
- Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…